$TRDA
Entrada Therapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000168937522000004 Filed on May 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.433M
YoY Change
% of Gross Profit
Research & Development $15.72M $6.223M
YoY Change 152.58%
% of Gross Profit
Depreciation & Amortization $400.0K $200.0K
YoY Change 100.0%
% of Gross Profit
Operating Expenses $22.15M $8.393M
YoY Change 163.92%
Operating Profit -$22.15M -$8.393M
YoY Change 163.92%
Interest Expense $480.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $480.0K $13.00K
YoY Change 3592.31%
Pretax Income -$21.67M
YoY Change
Income Tax $0.00
% Of Pretax Income
Net Earnings -$21.67M -$8.380M
YoY Change 158.6% 78.83%
Net Earnings / Revenue
Basic Earnings Per Share -$0.69 -$6.67
Diluted Earnings Per Share -$0.69 -$6.67
COMMON SHARES
Basic Shares Outstanding 31.25M shares 1.256M shares
Diluted Shares Outstanding 31.25M shares 1.256M shares

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $263.9M
YoY Change
Cash & Equivalents $84.64M $146.2M
Short-Term Investments $179.3M
Other Short-Term Assets $8.810M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $272.7M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $7.197M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.434M
YoY Change
Total Long-Term Assets $43.99M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $272.7M
Total Long-Term Assets $43.99M
Total Assets $316.7M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.931M
YoY Change
Accrued Expenses $4.524M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.43M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $23.89M
YoY Change
Total Long-Term Liabilities $23.89M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $15.43M
Total Long-Term Liabilities $23.89M
Total Liabilities $39.31M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$115.3M
YoY Change
Common Stock $3.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $277.4M -$49.67M
YoY Change
Total Liabilities & Shareholders Equity $316.7M
YoY Change

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$21.67M -$8.380M
YoY Change 158.6% 78.83%
Depreciation, Depletion And Amortization $400.0K $200.0K
YoY Change 100.0%
Cash From Operating Activities -$20.99M -$8.336M
YoY Change 151.81%
INVESTING ACTIVITIES
Capital Expenditures $594.0K $908.0K
YoY Change -34.58%
Acquisitions
YoY Change
Other Investing Activities -$180.9M
YoY Change
Cash From Investing Activities -$181.5M -$908.0K
YoY Change 19892.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $50.00K $116.4M
YoY Change -99.96%
NET CHANGE
Cash From Operating Activities -$20.99M -$8.336M
Cash From Investing Activities -$181.5M -$908.0K
Cash From Financing Activities $50.00K $116.4M
Net Change In Cash -$202.5M $107.1M
YoY Change -288.98%
FREE CASH FLOW
Cash From Operating Activities -$20.99M -$8.336M
Capital Expenditures $594.0K $908.0K
Free Cash Flow -$21.59M -$9.244M
YoY Change 133.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001689375
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-40969
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
ENTRADA THERAPEUTICS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3983399
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
6 Tide Street
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02210
CY2022Q1 dei City Area Code
CityAreaCode
857
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
520-9158
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
TRDA
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31365567 shares
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84640000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
291064000 USD
CY2022Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
179262000 USD
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8810000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7636000 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
272712000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
298700000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7197000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6261000 USD
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3950000 USD
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
31409000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1434000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
872000 USD
CY2022Q1 us-gaap Assets
Assets
316702000 USD
CY2021Q4 us-gaap Assets
Assets
305833000 USD
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2931000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
706000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4524000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6013000 USD
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7971000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
15426000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6719000 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23885000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2022Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0 USD
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
396000 USD
CY2022Q1 us-gaap Liabilities
Liabilities
39311000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
7115000 USD
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31360983 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31264451 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31336092 shares
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2170000 USD
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31224336 shares
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
394263000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
392384000 USD
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1535000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115340000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-93669000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
277391000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
298718000 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
316702000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
305833000 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15718000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6223000 USD
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6433000 USD
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
22151000 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
8393000 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-22151000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8393000 USD
CY2022Q1 trda Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
480000 USD
CY2021Q1 trda Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
13000 USD
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
480000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21671000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8380000 USD
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.67
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.67
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31246916 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31246916 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1256487 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1256487 shares
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1535000 USD
CY2021Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1535000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23206000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8380000 USD
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
85299885 shares
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
81658000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-41490000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000 USD
CY2021Q1 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
8000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
164000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8380000 USD
CY2021Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
138821984 shares
CY2021Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
197489000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-49669000 USD
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
298718000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50000 USD
CY2022Q1 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
35000 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1794000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1535000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21671000 USD
CY2022Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2022Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
277391000 USD
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-21671000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-8380000 USD
CY2022Q1 us-gaap Depreciation
Depreciation
390000 USD
CY2021Q1 us-gaap Depreciation
Depreciation
199000 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1794000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
164000 USD
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-142000 USD
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1670000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
66000 USD
CY2022Q1 trda Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-1582000 USD
CY2021Q1 trda Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
0 USD
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
562000 USD
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-23000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2061000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-268000 USD
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1526000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-510000 USD
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1531000 USD
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0 USD
CY2022Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
0 USD
CY2021Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
502000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20991000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8336000 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
594000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
908000 USD
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
182653000 USD
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1714000 USD
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-181533000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-908000 USD
CY2022Q1 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
0 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
116248000 USD
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
50000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
29000 USD
CY2022Q1 trda Proceeds From Early Exercise Of Stock Options
ProceedsFromEarlyExerciseOfStockOptions
0 USD
CY2021Q1 trda Proceeds From Early Exercise Of Stock Options
ProceedsFromEarlyExerciseOfStockOptions
108000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
116385000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-202474000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
107141000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
291064000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39045000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88590000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146186000 USD
CY2022Q1 trda Deferred Financing Costs In Accounts Payable And Accrued Expenses
DeferredFinancingCostsInAccountsPayableAndAccruedExpenses
0 USD
CY2021Q1 trda Deferred Financing Costs In Accounts Payable And Accrued Expenses
DeferredFinancingCostsInAccountsPayableAndAccruedExpenses
418000 USD
CY2022Q1 trda Purchase Of Lessor Owned Assets Accrued Not Yet Paid
PurchaseOfLessorOwnedAssetsAccruedNotYetPaid
370000 USD
CY2021Q1 trda Purchase Of Lessor Owned Assets Accrued Not Yet Paid
PurchaseOfLessorOwnedAssetsAccruedNotYetPaid
0 USD
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
391000 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
462000 USD
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
32991000 USD
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2022Q1 trda Transfer Of Deposits For Equipment From Operating To Investing Cash Flows
TransferOfDepositsForEquipmentFromOperatingToInvestingCashFlows
495000 USD
CY2021Q1 trda Transfer Of Deposits For Equipment From Operating To Investing Cash Flows
TransferOfDepositsForEquipmentFromOperatingToInvestingCashFlows
0 USD
CY2022Q1 trda Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
35000 USD
CY2021Q1 trda Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
8000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21700000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8400000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115300000 USD
CY2022Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
263900000 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84640000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
291064000 USD
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
3950000 USD
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
0 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88590000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
291064000 USD
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
33400000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33000000 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
180797000 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1535000 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
179262000 USD
CY2022Q1 trda Number Of Securities
NumberOfSecurities
38 security
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
179300000 USD
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9003000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7677000 USD
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1806000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1416000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7197000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6261000 USD
CY2022Q1 us-gaap Depreciation
Depreciation
400000 USD
CY2021Q1 us-gaap Depreciation
Depreciation
200000 USD
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1630000 USD
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4077000 USD
CY2022Q1 trda Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
1616000 USD
CY2021Q4 trda Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
1032000 USD
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
744000 USD
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
419000 USD
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
534000 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
485000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4524000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6013000 USD
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8120262 shares
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1794000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
164000 USD
CY2021 trda Stock Issued During Period Shares Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions
111756 shares
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6583887 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 trda Stock Issued During Period Shares Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions
96532 shares
CY2021Q4 trda Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount
300000 USD
CY2022Q1 trda Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount
300000 USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3461870 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.38
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
999315 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.67
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
24891 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.00
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
23627 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.73
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4412667 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.72
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2385606 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.25
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y8M12D
CY2022Q1 us-gaap Lease Cost
LeaseCost
1890000 USD
CY2022Q1 trda Tenant Improvements Allowance
TenantImprovementsAllowance
19500000 USD
CY2022Q1 us-gaap Security Deposit
SecurityDeposit
800000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2242000 USD
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1890000 USD
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
0 USD
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1839000 USD
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0381
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
6735000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
9219000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
9494000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8650000 USD
CY2022Q1 trda Lessee Operating Lease Liability To Be Paid Due After Year Three
LesseeOperatingLeaseLiabilityToBePaidDueAfterYearThree
0 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
34098000 USD
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
31856000 USD
CY2022Q1 us-gaap Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1
LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
P10Y
CY2022Q1 us-gaap Lessee Operating Lease Lease Not Yet Commenced Renewal Term1
LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
P5Y
CY2022Q1 trda Operating Leases Rental Expenses Initial Fixed Monthly Rental Payments First12 Months
OperatingLeasesRentalExpensesInitialFixedMonthlyRentalPaymentsFirst12Months
500000 USD
CY2022Q1 trda Number Of Square Feet In Lease Agreement
NumberOfSquareFeetInLeaseAgreement
65000 sqft
CY2022Q1 trda Operating Leases Rental Expenses Annual Increase
OperatingLeasesRentalExpensesAnnualIncrease
0.03
CY2022Q1 trda Initial Fixed Rental Income Per Rentable Square Foot Of Premises Per Annum
InitialFixedRentalIncomePerRentableSquareFootOfPremisesPerAnnum
240.00
CY2022Q1 trda Operating Leases Additional Allowance
OperatingLeasesAdditionalAllowance
1600000 USD
CY2022Q1 trda Tenant Allowance Rentable Square Foot Of Premises Per Annum
TenantAllowanceRentableSquareFootOfPremisesPerAnnum
20.00
CY2022Q1 trda Interest Rate For Additional Improvements Allowance
InterestRateForAdditionalImprovementsAllowance
0.08
CY2022Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
3900000 USD
CY2022Q1 trda Operating Lease Related Expenses Prior To Commencement
OperatingLeaseRelatedExpensesPriorToCommencement
600000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21671000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8380000 USD
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31246916 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31246916 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1256487 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1256487 shares
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.67
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.67
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4806953 shares
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20837268 shares

Files In Submission

Name View Source Status
0001689375-22-000004-index-headers.html Edgar Link pending
0001689375-22-000004-index.html Edgar Link pending
0001689375-22-000004.txt Edgar Link pending
0001689375-22-000004-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
trda-20220331.htm Edgar Link pending
trda-20220331.xsd Edgar Link pending
trda-20220331x10qex311.htm Edgar Link pending
trda-20220331x10qex312.htm Edgar Link pending
trda-20220331x10qex321.htm Edgar Link pending
trda-20220331_cal.xml Edgar Link unprocessable
trda-20220331_def.xml Edgar Link unprocessable
trda-20220331_g1.jpg Edgar Link pending
trda-20220331_htm.xml Edgar Link completed
trda-20220331_lab.xml Edgar Link unprocessable
trda-20220331_pre.xml Edgar Link unprocessable